As many will know the General Data Protection Regulation, more commonly known as GDPR, came into effect across the European Union on May 25th. This regulation was approved in 2016 by the European Union, European Commission and European Parliament to protect the private data of European citizens that is held by third parties.
The RP Fighting Blindness Conference 2018 will provide a fantastic opportunity for participants to hear from a variety of speakers; to find out more about our charity; to gain information surrounding voice recognition software and much more!
Keynote speakers include:
MeiraGTx Ltd, a clinical stage gene therapy company based in London and New York, announced that the US FDA has granted Fast Track designation to their gene therapy product candidate, AAV-RPGR, for the treatment of X-linked retinitis pigmentosa (XLRP). XLRP is one of the most severe forms of retinitis pigmentosa (RP) that leads to blindness, for which there are currently no approved treatments.
Retina International is delighted to announce the appointment of Sarah McLoughlin as Science Communication Officer.
Sarah will be working on the implementation of RI’s communications strategy where she will play a key role in one of the organisations primary objectives: delivery of the latest information on relevant developments in research and innovation to members and stakeholders.
On World Health Day 2018, April 7th, the World Health Organization marks its 70th anniversary. Over the past seven decades, WHO has spearheaded efforts to rid the world of diseases like smallpox and to fight against deadly habits like tobacco use.
In 2018 World Health Day is dedicated to one of WHO’s founding principles:
“The enjoyment of the highest attainable standard of health is one of the fundamental rights of every human being without distinction of race, religion, and political belief, economic or social condition.”
Nightstar Therapeutics plc, a clinical-stage gene therapy company developing treatments for rare inherited retinal diseases, today announced the initiation of the company’s STAR Phase 3 registrational trial to study the safety and efficacy of NSR-REP1 in patients with choroideremia. In data from 32 patients treated with NSR-REP1 across four open-label Phase 1/2 clinical trials, over 90% of treated patients maintained or improved their visual acuity over a one-year follow-up period.
ViaOpta Hello Application
ViaOpta Hello is a multi-tool application that can assist blind or visually impaired people by using cognitive services and Microsoft latest image analysis technology to identify people, items, and scenes.
Foundation Fighting Blindness will provide up to $7.5 million in funding to develop ProQR’s candidate QR-421a for Usher syndrome type 2A 12
Foundation Fighting Blindness and ProQR have entered into a partnership to develop QR-421a for Usher syndrome type 2A, targeting mutations in exon 13 of the causative USH2A gene. Foundation Fighting Blindness will provide milestone-based co-funding of up to $7.5 million to ProQR to advance the program into the clinic. QR-421a received orphan drug designation from the FDA.
Report by Fraser Alexander & local organising committee
The biennial Retina International World Congress will be held in Auckland, from February 7th to 11th 2018. Now while you might be thinking that is still a whole year away, let’s remember just how quickly the last year flew by and think about making plans early!